SEC Form 4
Evommune, Inc. (EVMN) insider trading
In the 12 months to Nov 19, 2026, 6 EVMN insiders reported open-market sales of $2.3M across 8 filings; 3 insiders bought $163.6K.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $2.3M
- 8 filings · 6 insiders
- Open-market purchases
- $163.6K
- 3 filings
- Pre-arranged sales (10b5-1)
- 8 of 8
- All $2.3M sold was pre-arranged
Who traded EVMN, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
EVMN daily close from Nov 19, 2025 to Nov 18, 2026, between $5.10 and $31.57, last $6.88. 8 sale and 3 purchase filings by 8 insiders, marked at their filing dates. Luis C. Pena, President & CEO: sold $550.7K across 2 filings, first filed Jun 3, 2026, last Jun 24, 2026. Janice Suzann Drew, Chief of Dev. Operations: sold $452.6K across 1 filing, first filed Jun 24, 2026, last Jun 24, 2026. Kyle Carver, Chief Financial Officer: sold $415.1K and bought $13.3K across 2 filings, first filed Jun 1, 2026, last Jul 10, 2026. Jeegar Pravinkumar Patel, Chief Scientific Officer: sold $412.9K across 2 filings, first filed Jun 3, 2026, last Jun 24, 2026. Gregory S. Moss, Chief Business & Legal Officer: sold $324.7K across 1 filing, first filed Jun 1, 2026, last Jun 1, 2026. Arthur S. Kirsch, Director: bought $133.0K across 1 filing, first filed Jul 8, 2026, last Jul 8, 2026. David E. Cohen, Director: sold $123.1K across 1 filing, first filed Jun 3, 2026, last Jun 3, 2026. Robert Lorne Hopfner, Director: bought $17.4K across 1 filing, first filed Dec 22, 2025, last Dec 22, 2025.
Largest mark · tap a row for others
Janice Suzann Drew · Chief of Dev. Operations
Sale $452,600
20,000 shares at $22.63 avg
Filed Jun 24, 2026 · traded Jun 22
Pre-arranged (10b5-1) · close on filing date $23.56
Luis C. Pena · President & CEO
President & CEO
$550.7K soldJanice Suzann Drew · Chief of Dev. Operations
Chief of Dev. Operations
$452.6K soldKyle Carver · Chief Financial Officer
Chief Financial Officer
$415.1K sold$13.3K boughtJeegar Pravinkumar Patel · Chief Scientific Officer
Chief Scientific Officer
$412.9K soldGregory S. Moss · Chief Business & Legal Officer
Chief Business & Legal Officer
$324.7K soldArthur S. Kirsch · Director
Director
$133.0K boughtDavid E. Cohen · Director
Director
$123.1K soldRobert Lorne Hopfner · Director
Director
$17.4K boughtOpen-market trades
11 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Luis C. Pena | President & CEO | $550.7K | — | 2 | 100% of sales | |
| Janice Suzann Drew | Chief of Dev. Operations | $452.6K | — | 1 | 100% of sales | |
| Kyle Carver | Chief Financial Officer | $415.1K | $13.3K | 2 | 100% of sales | |
| Jeegar Pravinkumar Patel | Chief Scientific Officer | $412.9K | — | 2 | 100% of sales | |
| Gregory S. Moss | Chief Business & Legal Officer | $324.7K | — | 1 | 100% of sales | |
| Arthur S. Kirsch | Director | — | $133.0K | 1 | — | |
| David E. Cohen | Director | $123.1K | — | 1 | 100% of sales | |
| Robert Lorne Hopfner | Director | — | $17.4K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Kyle Carver Chief Financial Officer | Purchase | 1,000 | $13.26 | $13.3K | 60,335 | |
traded | Arthur S. Kirsch Director | Purchase | 10,000 | $13.30 | $133.0K | 10,000 | |
traded | Luis C. Pena President & CEO | SalePre-arranged (10b5-1) | 7,438 | $22.71 | $168.9K | 630,458 | |
traded | Janice Suzann Drew Chief of Dev. Operations | SalePre-arranged (10b5-1) | 20,000 | $22.63 | $452.6K | 67,794 | |
traded | Jeegar Pravinkumar Patel Chief Scientific Officer | SalePre-arranged (10b5-1) | 1,488 | $22.50 | $33.5K | 46,403 | |
traded | David E. Cohen Director | SalePre-arranged (10b5-1) | 6,056 | $20.33 | $123.1K | 17,609 | |
traded | Luis C. Pena President & CEO | SalePre-arranged (10b5-1) | 16,787 | $22.74 | $381.7K | 637,896 | |
traded | Jeegar Pravinkumar Patel Chief Scientific Officer | SalePre-arranged (10b5-1) | 16,687 | $22.74 | $379.5K | 46,403 | |
traded | Gregory S. Moss Chief Business & Legal Officer | SalePre-arranged (10b5-1) | 14,223 | $22.83 | $324.7K | 60,835 | |
traded | Kyle Carver Chief Financial Officer | SalePre-arranged (10b5-1) | 18,175 | $22.84 | $415.1K | 59,335 | |
traded | Robert Lorne Hopfner Director | Purchase | 1,000 | $17.35 | $17.4K | 4,026 |
GET /stocks/filings/vX/form-4?tickers=EVMN&filing_date.gte=2025-11-19&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"EVMN"
],
"issuer_cik": "0002044725",
"owner_cik": "0001757072",
"accession_number": "0001757072-26-000007",
"form_type": "4",
"filing_date": "2026-07-10",
"period_of_report": "2026-07-08",
"issuer_name": "Evommune, Inc.",
"issuer_trading_symbol": "EVMN",
"owner_name": "Carver Kyle",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Financial Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-07-08",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 1000,
"transaction_price_per_share": 13.26,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 60335,
"transaction_value": 13260,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The purchase by the reporting person reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the sales of 1,000 shares of the Issuer's common stock by the reporting person at the price of $23.42 per share on May 28, 2026. The reporting person has agreed to pay to the Issuer upon settlement of the purchase, $10,160, representing the full amount of the profit realized in connection with the short-swing transaction."
}
]
},
{
"tickers": [
"EVMN"
],
"issuer_cik": "0002044725",
"owner_cik": "0001290976",
"accession_number": "0001290976-26-000004",
"form_type": "4",
"filing_date": "2026-07-08",
"period_of_report": "2026-07-07",
"issuer_name": "Evommune, Inc.",
"issuer_trading_symbol": "EVMN",
"owner_name": "KIRSCH ARTHUR S",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-07-07",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 10000,
"transaction_price_per_share": 13.3,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 10000,
"transaction_value": 133000,
"not_subject_to_section_16": false,
"direct_or_indirect": "I",
"nature_of_ownership": "By Trust",
"footnotes": [
{
"id": "F1",
"description": "The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.25 to $13.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."
},
{
"id": "F2",
"description": "The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 16 records
- Option exercises6 records
- Tax withholding6 records
- Grants and awards4 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Evommune, Inc.'s CEO sold stock?
Yes. Luis C. Pena (CEO) sold 24,225 shares ($550.7K) in Jun 2026, all under a pre-arranged 10b5-1 plan.
How current is EVMN’s insider data?
These are EVMN Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track EVMN insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for EVMN every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.